Ziritaxestat

DB15403InvestigationalSmall molecule

Ziritaxestat is under investigation in clinical trial NCT03798366 (A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis).

Mechanism: Pharmacologically active on Autotaxin
Curator reviewed
Formula / weight: C₃₀H₃₃FN₈O₂S · 588.71 g/mol (avg)
Also known as: 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile
Code names: GLPG-1690

Resolves to

Compound

UNIII02418V13WCAS1628260-79-6ChEMBLCHEMBL3828074

Structure

InChIKeyREQQVBGILUTQNN-UHFFFAOYSA-NSMILESCCC1=C(N(C)C2=NC(=C(S2)C#N)C2=CC=C(F)C=C2)N2C=C(C=C(C)C2=N1)N1CCN(CC(=O)N2CC(O)C2)CC1

Targets

Q13822ENPP2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ziritaxestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account